Bank of America Comments on Generic Injectables


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


Bank of America has conducted an “in-depth analysis of the injectable pharmaceuticals market, which includes: (1) the patent cycle, ie, branded product sales value that may be available to the generic injectable industry over the next 10 years (2011-2020); (2) an assessment of the current generic injectables market environment; (3) a review of mergers and acquisitions in the generic injectable industry, which in keeping with the broader generic pharma trend, continues to consolidate; and (4) a brief summary of current issues (product shortages, manufacturing issues, recalls).”“We note that our analysis is US centric and more about companies than stocks. Moreover, our analysis does not include biologics, which account for a significant and growing portion of the injectable market,” Bank of America writes.

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: Analyst RatingsBank of Americageneric injectablesinjectable market